CARAT - Chimeric Antigen Receptors (CARs) for Advanced Therapies
an EU-funded collaborative research project involving 8 partners from 4 different European countries (France, Germany, Italy & United Kingdom).
- CARAT's goal
is to develop an efficient and safe technology platform for advanced cellular therapies, namely to manufacture CAR T-cell products for personalized treatment of cancer patients.
- Recent Success Stories
of CAR-based therapies have raised enormous expectations to cure severely ill patients: CARs were introduced into cells of the immune system, typically T-cells, by genetic engineering.
- Initial clinical studies
demonstrated considerable evidence that these artificial recognition molecules allow specific targeting of immune responses towards complete and stable eradication of cancer cells.
- Translation into the clinic
of such advanced therapeutic concepts is extremely difficult as the manufacture of CAR-modified T-cells is technologically complex and expensive.
- The CARAT technology platform
will thus enable the automated, safe, and cost efficient manufacture of more effective CAR-modified T-cells. Thereby, CARAT will spread the clinical use of CAR T-cell technologies with the ultimate goal of serving patients with so far incurable hematologic malignancies and solid tumours like colon, pancreas or lung cancer – everywhere in Europe.
The CARAT consortium comprises a multi-national team of leading experts from eight European partnering institutions.
Recent success stories of cancer therapy with CAR-modified T-cells have raised enormous scientific and public expectations to cure severely ill patients.
This study commissioned by the European Patent Office demonstrates the application of patent information to gain insights into specific technological...
To enable more and more experts to use innovative cell manufacturing technology: this is the goal of the CARAT Training Fellowship Programme. In...
Front Oncol 2019 Feb 14;9:52. doi: 10.3389/fonc.2019.00052. eCollection 2019.
Mol Ther Methods Clin Dev. 2019 Mar 16;13:371-379. doi: 10.1016/j.omtm.2019.03.003. eCollection 2019 Jun 14.
In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndrome
EMBO Mol Med Sep 17 [Epub ahead of print]